| Biovail Laboratories International (Barbados) S.R.L. Patent applications |
| Patent application number | Title | Published |
|---|
| 20110190333 | DIHYDROTETRABENANZINE FOR THE TREATMENT OF ANXIETY - The invention provides a 3,11b-cis-dihydrotetrabenazine of the formula (Ib): or a pharmaceutically acceptable salt thereof for use in the prophylaxis or treatment of anxiety. | 08-04-2011 |
| 20110053866 | PHARMACEUTICAL COMPOSITIONS - The present invention provides for a pharmaceutical composition that includes tetrabenazine and a release-retarding agent; and a method of treating a hyperkinetic movement disorder (e.g., Huntington's disease, chorea associated with Huntington's disease, hemiballismus, senile chorea, tic disorders, tardive dyskinesia, myoclonus, dystonia and/or Tourette's syndrome). The method includes administering an effective amount of the pharmaceutical composition, for a period of time effective to treat the hyperkinetic movement disorder. | 03-03-2011 |
| 20110039877 | USE OF 3, 11B-CIS-DIHYDROTETRABENAZINE IN THE TREATMENT OF MULTIPLE SCLEROSIS AND AUTOIMMUNE MYELITIS - The invention provides a compound for use in treating multiple sclerosis wherein the compound is a 3, 11b-cis-dihydrotetrabenazine of the formula (Ia): or a pharmaceutically acceptable salt thereof. | 02-17-2011 |
| 20100087476 | PHARMACEUTICAL COMPOUNDS - This application describes methods of treatment and/or prophylaxis of asthma that involve administration of dihydrotetrabenazine, and isomers and/or pharmaceutically acceptable salts thereof. | 04-08-2010 |
| 20100063086 | PHARMACEUTICAL COMPOUNDS - This application describes method of treating dementia and cognitive deficits associated with dementia that involve administration of dihydrotetrabenazine, and isomers and/or pharmaceutically acceptable salts thereof. | 03-11-2010 |
| 20100055133 | PHARMACEUTICAL COMPOSITIONS - The present invention provides for a pharmaceutical composition that includes tetrabenazine and a release-retarding agent; and a method of treating a hyperkinetic movement disorder (e.g., Huntington's disease, chorea associated with Huntington's disease, hemiballismus, senile chorea, tic disorders, tardive dyskinesia, myoclonlus, dystoniia and/or Tourette's syndrome). The method includes administering an effective amount of the pharmaceutical composition, for a period of time effective to treat the hyperkinetic movement disorder. | 03-04-2010 |
